Skip to main content

BriaCell Therapeutics Corp.

corporate_fare Company Profile

BriaCell Therapeutics Corp.

BCTX·NASDAQ·Life Sciences·CIK 0001610820

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care. Immunotherapies harness the body's own immune system to recognize and destroy cancer cells. The company is advancing its Bria-IMT™ targeted immunotherapy in combination with an immune checkpoint inhibitor (Retifanlimab®) in a pivotal Phase 3 study in metastatic breast cancer (ClinicalTrials.gov: NCT06072612). Bria-IMT™ is under Fast Track Designation by the U.S. Food and Drug Administration (FDA), intended to accelerate review of novel treatments addressing unmet medical needs. Positive completion of the pivotal study, following FDA review, could lead to full approval of the Bria-IMT™ immune checkpoint inhibitor combination in metastatic breast cancer. BriaCell has reported benchmark-beating patient survival and clinical benefit in metastatic breast cancer, with median overall survival of 13.3 months for the Phase 3 sequence in BriaCell's metastatic breast cancer patients versus median overall survival reported in the literature and in its Phase 2 study of the Bria-IMT™ combination study with Retifanlimab®. Additionally, BriaCell reported median overall survival of 16.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitor in patients treated with the Phase 3 formulation since 2022 (post-COVID). A completed Bria-IMT™ Phase 1/2 combination study with Retifanlimab® (an anti-PD1 antibody manufactured by Incyte Corporation) confirmed tolerability and early-stage efficacy (ClinicalTrials.gov: NCT03328026). BriaCell's Phase 1/2 study of Bria-OTS™, the company's personalized off-the-shelf immunotherapy, in metastatic breast cancer is ongoing (ClinicalTrials.gov: NCT06471673). The first patient treated with 4 inoculations of cells (single agent) demonstrated complete resolution of a lung metastasis. BriaCell is developing Bria-OTS™ and its advanced form, Bria-OTS+™, as a platform technology for personalized off-the-shelf immunotherapies for numerous types of cancer.

BriaCell Therapeutics Corp. (NASDAQ:BCTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for BCTX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • BriaCell Secures $30M Public Offering at Premium to Market, Bolstering Clinical Pipeline
  • BriaCell Therapeutics Announces Highly Dilutive $30M Unit Offering at Deep Discount to Market Price
  • BriaCell Therapeutics Registers Additional $11.56M in Securities Offering, Signaling Substantial Dilution

Financial Snapshot

Fiscal year ended July 31, 2026
Net Income
-$34.9M
Diluted EPS
-$6.97
Op. Cash Flow
-$28.65M
Free Cash Flow
-$28.78M
Operating Income
-$36.05M
Cash & Equivalents
$9.85M
Debt / Equity
0.00×
Shares Outstanding
8.71M sh
Source: 10-K · filed 2026-10-28 · accession 0001493152-26-049041
$3.1 +1.31% today
52-week range · as of 2026-10-28 $2.6 – $13.8
Market cap
$26.72M
Volume
109.7K (1.7× avg)
3-mo avg 64.4K
Live data · 2026-11-22 04:39 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BCTX - Filings & News (Page 2)

BCTX
Jan 15, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.55
Real-time Price: $3.10 info
Change: -$1.45 (-32%) info
Market Cap: $26.721M info
BCTX
Jan 14, 2026, 4:15 PM EST
Filing Type: 424B4
Importance Score:
9
Price at Filing: $4.83
Real-time Price: $3.10 info
Change: -$1.73 (-36%) info
Market Cap: $26.721M info
BCTX
Jan 13, 2026, 8:57 PM EST
Filing Type: S-1MEF
Importance Score:
9
Price at Filing: $4.88
Real-time Price: $3.10 info
Change: -$1.78 (-36%) info
Market Cap: $26.721M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets